Skip to main content

Advertisement

SpringerLink
Log in

Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development

  • Review
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Adenomyosis is an estrogen-dependent gynecologic disease characterized by the presence of endometrial tissue within the myometrium. Adenomyosis presents with abnormal uterine bleeding, pelvic pains, and infertility. This review aimed to investigate the major estrogen downstream effectors involved in the process of adenomyosis development and their potential use for nonhormonal treatment. A literature search was performed for preclinical and clinical studies published between January 2010 and November 2021 in the PubMed and Google Scholar databases using a combination of specific terms. Adenomyosis presents with a wide spectrum of clinical manifestations from asymptomatic to severe through a complex process involving a series of molecular changes associated with inflammation, invasion, angiogenesis, and fibrosis. Adenomyosis may develop through a multistep process, including the acquisition of (epi)genetic mutations, tissue injury caused at the endometrial–myometrial interface, inside-to-outside invasion (from the endometrial side into the uterine wall), or outside-to-inside invasion (from the serosal side into the uterine wall), and epithelial–mesenchymal transition, tissue repair or remodeling in the myometrium. These processes can be regulated by increased estrogen biosynthesis and progesterone resistance. The expression of estrogen downstream effectors associated with persistent inflammation, fragile and more permeable vessel formation, and tissue injury and remodeling may be correlated with dysmenorrhea, heavy menstrual bleeding, and infertility, respectively. Key estrogen downstream targets (e.g., WNT/β-catenin, transforming growth factor-β, and nuclear factor-κB) may serve as hub genes. We reviewed the molecular mechanisms underlying the development of adenomyosis and summarized potential nonhormonal therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author.

References

  1. Senturk LM, Imamoglu M. Adenomyosis: what is new? Womens Health (Lond). 2015;11(5):717–24.

    Article  CAS  PubMed  Google Scholar 

  2. Lacheta J. Uterine adenomyosis: pathogenesis, diagnostics, symptomatology and treatment. Ceska Gynekol. 2019;84(3):240–6.

    CAS  PubMed  Google Scholar 

  3. Harmsen MJ, Wong CFC, Mijatovic V, Griffioen AW, Groenman F, Hehenkamp WJK, et al. Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review. Hum Reprod Update. 2019;25(5):647–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Xiaoyu L, Weiyuan Z, Ping J, Anxia W, Liane Z. Serum differential proteomic analysis of endometriosis and adenomyosis by iTRAQ technique. Eur J Obstet Gynecol Reprod Biol. 2014;182:62–5.

    Article  PubMed  Google Scholar 

  5. Maruyama S, Imanaka S, Nagayasu M, Kimura M, Kobayashi H. Relationship between adenomyosis and endometriosis; different phenotypes of a single disease? Eur J Obstet Gynecol Reprod Biol. 2020;253:191–7.

    Article  PubMed  Google Scholar 

  6. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kobayashi H, Matsubara S, Imanaka S. Relationship between magnetic resonance imaging-based classification of adenomyosis and disease severity. J Obstet Gynaecol Res. 2021;47(7):2251–60.

    Article  PubMed  Google Scholar 

  8. Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet. 2009;280(4):529–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Leyendecker G, Wildt L. A new concept of endometriosis and adenomyosis: tissue injury and repair (TIAR). Horm Mol Biol Clin Investig. 2011;5(2):125–42.

    CAS  PubMed  Google Scholar 

  10. Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update. 2014;20(3):386–402.

    Article  CAS  PubMed  Google Scholar 

  11. Benagiano G, Brosens I. The endometrium in adenomyosis. Womens Health (Lond). 2012;8(3):301–12.

    Article  CAS  PubMed  Google Scholar 

  12. Kobayashi H, Kishi Y, Matsubara S. Mechanisms underlying adenomyosis-related fibrogenesis. Gynecol Obstet Invest. 2020;85(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  13. Bourdon M, Santulli P, Jeljeli M, Vannuccini S, Marcellin L, Doridot L, et al. Immunological changes associated with adenomyosis: a systematic review. Hum Reprod Update. 2021;27(1):108–29.

    Article  CAS  PubMed  Google Scholar 

  14. Bulun SE, Gurates B, Fang Z, Tamura M, Sebastian S, Zhou J, et al. Mechanisms of excessive estrogen formation in endometriosis. J Reprod Immunol. 2002;55(1):21–33.

    Article  CAS  PubMed  Google Scholar 

  15. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med. 2020;38(2–03):129–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100: 102287.

    Article  CAS  PubMed  Google Scholar 

  18. Reske JJ, Wilson MR, Holladay J, Wegener M, Adams M, Chandler RL. SWI/SNF inactivation in the endometrial epithelium leads to loss of epithelial integrity. Hum Mol Genet. 2020;29(20):3412–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Oie S, Matsuzaki K, Yokoyama W, Murayama A, Yanagisawa J. HDAC3 regulates stability of estrogen receptor alpha mRNA. Biochem Biophys Res Commun. 2013;432(2):236–41.

    Article  CAS  PubMed  Google Scholar 

  20. Liu X, Nie J, Guo SW. Elevated immunoreactivity against class I histone deacetylases in adenomyosis. Gynecol Obstet Invest. 2012;74(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  21. Liu Xishi, Yuan Lei, Guo SW. Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci. 2010;17(10):904–12.

    Article  CAS  Google Scholar 

  22. Campo S, Campo V, Benagiano G. Adenomyosis and infertility. Reprod Biomed Online. 2012;24(1):35–46.

    Article  PubMed  Google Scholar 

  23. Li T, Li YG, Pu DM. Matrix metalloproteinase-2 and -9 expression correlated with angiogenesis in human adenomyosis. Gynecol Obstet Invest. 2006;62(4):229–35.

    Article  CAS  PubMed  Google Scholar 

  24. Yi KW, Kim SH, Ihm HJ, Oh YS, Chae HD, Kim CH, Kang BM. Increased expression of p21-activated kinase 4 in adenomyosis and its regulation of matrix metalloproteinase-2 and -9 in endometrial cells. Fertil Steril. 2015;103(4):1089-1097.e2.

    Article  CAS  PubMed  Google Scholar 

  25. Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H, Zhou YF. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood). 2001;226(5):429–33.

    Article  CAS  PubMed  Google Scholar 

  26. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400.

    Article  PubMed  Google Scholar 

  27. Park H, Kim SH, Cho YM, Ihm HJ, Oh YS, Hong SH, et al. Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis. Obstet Gynecol Sci. 2016;59(2):123–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yu J, Chen LH, Zhang B, Zheng QM. The modulation of endometriosis by lncRNA MALAT1 via NF-kappaB/iNOS. Eur Rev Med Pharmacol Sci. 2019;23(10):4073–80.

    CAS  PubMed  Google Scholar 

  29. Oh SJ, Shin JH, Kim TH, Lee HS, Yoo JY, Ahn JY, et al. β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J Pathol. 2013;231(2):210–22.

    Article  CAS  PubMed  Google Scholar 

  30. Klemmt PAB, Starzinski-Powitz A. Molecular and Cellular Pathogenesis of Endometriosis. Curr Womens Health Rev. 2018;14(2):106–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yang JH, Chen MJ, Wu MY, Chen YC, Yang YS, Ho HN. Decreased suppression of interleukin-6 after treatment with medroxyprogesterone acetate and danazol in endometrial stromal cells of women with adenomyosis. Fertil Steril. 2006;86(5):1459–65.

    Article  CAS  PubMed  Google Scholar 

  32. Wang Q, Wang L, Shao J, Wang Y, Jin LP, Li DJ, et al. L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner. Int J Clin Exp Pathol. 2014;7(9):5762–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis. Am J Reprod Immunol. 2002;47(4):251–5.

    Article  PubMed  Google Scholar 

  34. Carrarelli P, Yen CF, Funghi L, Arcuri F, Tosti C, Bifulco G, et al. Expression of inflammatory and neurogenic mediators in adenomyosis. Reprod Sci. 2017;24(3):369–75.

    Article  CAS  PubMed  Google Scholar 

  35. Makrigiannakis A, Vrekoussis T, Zoumakis E, Hatzidakis V, Vlachou E, Salakos N, et al. Endometrial CRH and implantation: from bench to bedside. Hormones (Athens). 2018;17(3):293–7.

    Article  PubMed  Google Scholar 

  36. AlAshqar A, Reschke L, Kirschen GW, Borahay MA. Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies. Biol Reprod. 2021;105(1):7–31.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Prašnikar E, Kunej T, Knez J, Repnik K, Potočnik U, Kovačič B. Determining the molecular background of endometrial receptivity in adenomyosis. Biomolecules. 2020;10(9):1311.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Kay N, Huang CY, Shiu LY, Yu YC, Chang Y, Schatz F, et al. TGF-beta1 neutralization improves pregnancy outcomes by restoring endometrial receptivity in mice with adenomyosis. Reprod Sci. 2021;28(3):877–87.

    Article  CAS  PubMed  Google Scholar 

  39. Zhou Y, Peng Y, Xia Q, Yan D, Zhang H, Zhang L, et al. Decreased Indian hedgehog signaling activates autophagy in endometriosis and adenomyosis. Reproduction. 2021;161(2):99–109.

    Article  CAS  PubMed  Google Scholar 

  40. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A. 2009;106(46):19497–502.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Shang WQ, Yu JJ, Zhu L, Zhou WJ, Chang KK, Wang Q, et al. Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells. Am J Transl Res. 2015;7(10):1782–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Exacoustos C, Morosetti G, Conway F, Camilli S, Martire FG, Lazzeri L, et al. New sonographic classification of adenomyosis: do type and degree of adenomyosis correlate to severity of symptoms? J Minim Invasive Gynecol. 2020;27(6):1308–15.

    Article  PubMed  Google Scholar 

  43. Zhou S, Yi T, Liu R, Bian C, Qi X, He X, et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics. 2012;11(7):M112.017988.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Liu X, Nie J, Guo SW. Elevated immunoreactivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis. Hum Reprod. 2011;26(2):337–45.

    Article  CAS  PubMed  Google Scholar 

  45. Li B, Chen M, Liu X, Guo SW. Constitutive and tumor necrosis factor-alpha-induced activation of nuclear factor-kappaB in adenomyosis and its inhibition by andrographolide. Fertil Steril. 2013;100(2):568–77.

    Article  CAS  PubMed  Google Scholar 

  46. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update. 1998;4(4):312–22.

    Article  CAS  PubMed  Google Scholar 

  47. Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod. 2007;22(5):1450–6.

    Article  CAS  PubMed  Google Scholar 

  48. García-Solares J, Donnez J, Donnez O, Dolmans MM. Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril. 2018;109(3):371–9.

    Article  PubMed  Google Scholar 

  49. Shen M, Liu X, Zhang H, Guo SW. Transforming growth factor beta1 signaling coincides with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis in mice. Hum Reprod. 2016;31(2):355–69.

    CAS  PubMed  Google Scholar 

  50. Yoo JY, Ku BJ, Kim TH, Il Ahn J, Ahn JY, Yang WS, Lim JM, Taketo MM, Shin JH, Jeong JW. beta-catenin activates TGF-beta-induced epithelial-mesenchymal transition in adenomyosis. Exp Mol Med. 2020;52(10):1754–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang T, Yuan J, Zhang J, Tian R, Ji W, Zhou Y, et al. Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. Oncotarget. 2015;6(31):30975–92.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kadota T, Fujita Y, Araya J, Watanabe N, Fujimoto S, Kawamoto H, et al. Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-beta-WNT crosstalk. J Extracell Vesicles. 2021;10(10):e12124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. An M, Li D, Yuan M, Li Q, Zhang L, Wang G. Different macrophages equally induce EMT in endometria of adenomyosis and normal. Reproduction. 2017;154(1):79–92.

    Article  CAS  PubMed  Google Scholar 

  54. An M, Li D, Yuan M, Li Q, Zhang L, Wang G. Interaction of macrophages and endometrial cells induces epithelial-mesenchymal transition-like processes in adenomyosis. Biol Reprod. 2017;96(1):46–57.

    PubMed  Google Scholar 

  55. Maia H Jr, Haddad C, Pinheiro N, Casoy J. The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis. Int J Womens Health. 2013;5:293–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Maia H Jr, Haddad C, Casoy J. Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis. Int J Women’s Health. 2012;4:61–5.

    Article  Google Scholar 

  57. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83:149–55.

    Article  CAS  PubMed  Google Scholar 

  58. Ezaki K, Motoyama H, Sasaki H. Immunohistologic localization of estrone sulfatase in uterine endometrium and adenomyosis. Obstet Gynecol. 2001;98:815–9.

    CAS  PubMed  Google Scholar 

  59. Urabe M, Yamamoto T, Kitawaki J, Honjo H, Okada H. Estrogen biosynthesis in human uterine adenomyosis. Acta Endocrinol (Copenh). 1989;121(2):259–64.

    CAS  PubMed  Google Scholar 

  60. Zeng YY, Guan YG, Li KY. Role of estrogen, estrogen receptors, and aromatase in the pathogenesis of uterine adenomyosis. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37(3):383–7.

    CAS  PubMed  Google Scholar 

  61. Zhao L, Zhou S, Zou L, Zhao X. The expression and functionality of stromal caveolin 1 in human adenomyosis. Hum Reprod. 2013;28(5):1324–38.

    Article  CAS  PubMed  Google Scholar 

  62. Donnez J, Stratopoulou CA, Dolmans MM. Uterine adenomyosis: from disease pathogenesis to a new medical approach using GnRH antagonists. Int J Environ Res Public Health. 2021;18(19):9941.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011;95(7):2228-2235.el.

    Article  CAS  PubMed  Google Scholar 

  64. Li Y, Zou S, Xia X, Zhang S. Human adenomyosis endometrium stromal cells secreting more nerve growth factor: impact and effect. Reprod Sci. 2015;22(9):1073–82.

    Article  CAS  PubMed  Google Scholar 

  65. Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril. 2013;99(1):231–40.

    Article  CAS  PubMed  Google Scholar 

  66. Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010;202(4):346.e1-8.

    Article  PubMed  Google Scholar 

  67. Duckitt K. Menorrhagia. BMJ. Clin Evid. 2015;2015:0805.

    Google Scholar 

  68. Orazov MR, Nosenko EN, Radzinsky VE, Khamoshina MB, Lebedeva MG, Sounov MA. Proangiogenic features in chronic pelvic pain caused by adenomyosis. Gynecol Endocrinol. 2016;32:7–10.

    Article  CAS  PubMed  Google Scholar 

  69. Guo S, Zhang D, Lu X, Zhang Q, Gu R, Sun B, et al. Hypoxia and its possible relationship with endometrial receptivity in adenomyosis: a preliminary study. Reprod Biol Endocrinol. 2021;19(1):7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Quiñonez-Flores CM, González-Chávez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis. J Biomed Sci. 2016;23(1):62.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Huang TS, Chen YJ, Chou TY, Chen CY, Li HY, Huang BS, et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med. 2014;18(7):1358–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Karel C, Michal J, Radovan P, Pavel V, Jana Ž, Jan V, et al. Adenomyosis - its possible effect on endometrial function and receptivity. Ceska Gynekol. 2021;86(3):205–9.

    Article  Google Scholar 

  73. Patterson AL, Pirochta J, Tufano SY, Teixeira JM. Gain-of-function beta-catenin in the uterine mesenchyme leads to impaired implantation and decidualization. J Endocrinol. 2017;233(1):119–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Peng Y, Jin Z, Liu H, Xu C. Impaired decidualization of human endometrial stromal cells from women with adenomyosis. Biol Reprod. 2021;104(5):1034–44.

    Article  PubMed  Google Scholar 

  75. Ashary N, Laheri S, Modi D. Homeobox genes in endometrium: from development to decidualization. Int J Dev Biol. 2020;64(1-2–3):227–37.

    Article  PubMed  Google Scholar 

  76. Wang J, Huang C, Jiang R, Du Y, Zhou J, Jiang Y, et al. Decreased endometrial il-10 impairs endometrial receptivity by downregulating HOXA10 expression in women with adenomyosis. Biomed Res Int. 2018;2018:2549789.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Nusse R. Wnt signaling. Cold Spring Harb Perspect Biol. 2012;4:a011163.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, et al. Malignant glioma subset from actuate 1801: phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies. Neurooncol Adv. 2022;74(1):vdac012.

    Google Scholar 

  79. Li X, Liu Y, Zhao Y, Tian W, Zhai L, Pang H, et al. Rhein derivative 4F inhibits the malignant phenotype of breast cancer by downregulating Rac1 protein. Front Pharmacol. 2020;11:754.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Zhou G, Peng F, Zhong Y, Chen Y, Tang M, Li D. Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells. Int J Oncol. 2017;50(3):933–41.

    Article  CAS  PubMed  Google Scholar 

  81. Feng T, Wei S, Wang Y, Fu X, Shi L, Qu L, Fan X. Rhein ameliorates adenomyosis by inhibiting NF-kappaB and beta-catenin signaling pathway. Biomed Pharmacother. 2017;94:231–7.

    Article  CAS  PubMed  Google Scholar 

  82. Massagué J. TGFbeta in Cancer. Cell. 2008;134(2):215–30.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Melzer C, Hass R, von der Ohe J, Lehnert H, Ungefroren H. The role of TGF-beta and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma. Cell Commun Signal. 2017;15(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Patel S, Tang J, Overstreet JM, Anorga S, Lian F, Arnouk A, et al. Rac-GTPase promotes fibrotic TGF-beta1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. FASEB J. 2019;33(9):9797–810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Rasmi RR, Sakthivel KM, Guruvayoorappan C. NF-kappaB inhibitors in treatment and prevention of lung cancer. Biomed Pharmacother. 2020;130:110569.

    Article  CAS  PubMed  Google Scholar 

  86. Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke J. Andrographolide, an anti-inflammatory multitarget drug: all roads lead to cellular metabolism. Molecules. 2020;26(1):5.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Liu L, Luo N, Guo J, Xie Y, Chen L, Cheng Z. Berberine inhibits growth and inflammatory invasive phenotypes of ectopic stromal cells: imply the possible treatment of adenomyosis. J Pharmacol Sci. 2018;137(1):5–11.

    Article  CAS  PubMed  Google Scholar 

  88. Ortiz LM, Lombardi P, Tillhon M, Scovassi AI. Berberine, an epiphany against cancer. Molecules. 2014;19(8):12349–67.

    Article  PubMed  Google Scholar 

  89. Yang JH, Wu MY, Chen MJ, Chen SU, Yang YS, Ho HN. Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in adenomyosis. Fertil Steril. 2009;91(5 Suppl):2193–8.

    Article  CAS  PubMed  Google Scholar 

  90. Vannuccini S, Luisi S, Tosti C, Sorbi F, Petraglia F. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.

    Article  PubMed  Google Scholar 

  91. Zhu B, Chen Y, Shen X, Liu X, Guo SW. Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. Reprod Biol Endocrinol. 2016;14(1):66.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, et al. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/beta-catenin signaling. J Clin Endocrinol Metab. 2013;98(8):E1305-1313.

    Article  CAS  PubMed  Google Scholar 

  93. Vasquez YM, Mazur EC, Li X, Kommagani R, Jiang L, Chen R, et al. FOXO1 is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization. Mol Endocrinol. 2015;29(3):421–33.

Download references

Acknowledgements

I thank Mrs. Toyomi Kobayashi for creating the figure.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Ms.Clinic MayOne, Kashihara, Nara, 634-0813, Japan

    Hiroshi Kobayashi

  2. Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara, 634-8522, Japan

    Hiroshi Kobayashi

Authors
  1. Hiroshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HK: conception and design, acquisition of data, analysis and interpretation of data, and writing the manuscript.

Corresponding author

Correspondence to Hiroshi Kobayashi.

Ethics declarations

Ethics Approval and Consent to Participate

Not applicable.

Patient Consent for Publication

Not applicable.

Competing interests

The author declares no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, H. Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development. Reprod. Sci. 30, 743–760 (2023). https://doi.org/10.1007/s43032-022-01036-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-022-01036-4

Keywords

Search

Navigation